Childhood Disintegrative Disorder Heller's Syndrome

Last updated by Peer reviewed by Dr Laurence Knott, MBBS
Last updated Meets Patient’s editorial guidelines

Added to Saved items
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Synonyms: dementia infantalis, disintegrative psychosis, social development regression

Childhood disintegrative disorder (CDD) is a rare disorder. In the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), CDD is merged into autistic spectrum disorder. CDD has a relatively late onset and causes regression of previously acquired skills in social, language and motor functioning.

The cause is unknown and affected children have often achieved normal developmental milestones before the regression of skills. The age of onset is variable, but is typically seen after three years of reaching normal milestones. The regression can be very rapid. Some children may appear to be responding to hallucinations, but the most common and distinct feature is the regression of previously attained attained skills.

The cause is unknown. CDD occurs in children who have had previously normal development who then appear to regress, sometimes rapidly. The condition can seem to develop in days or develop over time, and most commonly begins in the fourth year of life, although there is some variation[2] . Some consider the condition to be a childhood dementia, suggesting that brain deposition of amyloid is the cause of the condition, but no clear-cut pathophysiology is proven[3] .

CDD is extremely rare with an incidence of 1.7 in 100,000 children[4] .

Symptoms

Affected children show clinically significant losses of earlier acquired skills in at least two of the following:

  • Expressive language skills.
  • Receptive language skills.
  • Social skills and self-care skills.
  • Bowel or bladder control.
  • Play skills.
  • Motor skills.

Abnormal function also occurs in at least two of:

  • Social interaction.
  • Communication.
  • Repetitive interests or behaviours.

The child presents after at least two years of apparently normal development. The change occurs usually between the ages of 3 to 4 years, but generally before the age of 10 years.

  • The onset may be abrupt or gradual.
  • It can be severe enough that children are aware themselves of the regression, and may ask what is happening to them.
  • Usually parents and professionals have not previously noticed abnormalities in terms of language and non-verbal communication, social relationships, play, adaptive behaviour or emotional development.
  • A typical presentation would be of a child who is able to communicate in two- or three-word phrases losing this ability. They would eventually stop talking altogether or retain only fragments of their former speech.
  • There may be social and emotional problems, such as a child previously happy to be cuddled becoming averse to physical contact.
  • Some children describe or seem to be reacting to hallucinations.

Comparison with autism

  • The patient eventually shows similar social and communication deficits to those associated with severe or Kanner's autism. However, it is distinguishable from autism on the basis of the normal antecedent developmental history.
  • Children with CDD are more likely than autistic children to show fearfulness and early stereotypical behaviours[5] .
  • Epilepsy occurs much more frequently in children with CDD compared with autism[6] .
  • The degree of intellectual impairment in children with CDD appears to be more 'even' than when compared with autism, although the overall degree of impairment and outcome appears to be similar in both groups.

Signs

  • There are no specific confirmatory signs, and physical abnormalities are not usually found, although there may be minor abnormalities such as microcephaly or motor inco-ordination.
  • Careful CNS examination including fundoscopy is important to detect other possible causes of the symptoms.

The differential diagnosis incudes any of the other pervasive developmental disorders, eg autistic spectrum disorder, Rett's Syndrome, pervasive developmental disorder - not otherwise specified (PDD-NOS), or causes of general learning disability. Other specific conditions which need to be ruled out are:

Tests to exclude reversible underlying causes of the condition:

  • FBC.
  • U&E/glucose.
  • LFT.
  • TFT.
  • Heavy metal levels.
  • HIV testing.
  • Urine screening for aminoaciduria.
  • Neuroimaging studies.

These are normally carried out during initial assessment in secondary care. Electroencephalogram (EEG), MRI or CT scan are likely to be used to ensure an alternative diagnosis has not been missed.

General measures

Therapy is given, as with autism, tailored to the child's disabilities, needs and educational objectives. This may include:

  • Behavioural therapies, such as applied behaviour analysis, which aim to teach the child to relearn language, self-care and social skills systematically.
  • Environmental therapies such as sensory enrichment.
  • Medication:
    • Risperidone may be effective in improving behavioural symptoms in PDD[4] . However, there is little evidence of specific efficacy in CDD[7] .
    • Other antipsychotics, stimulants and selective serotonin reuptake inhibitors (SSRIs) are sometimes used in expert hands to help in the control of problematic behaviour, particularly aggression. There is a significant risk of neuroleptic malignant syndrome with the use of neuroleptic medication.
    • Epilepsy may require anti-epileptic medication.
  • Loss of skills often reaches a plateau by around age 10. There may be some, very limited improvement, but this is seen in a minority of cases.
  • In the long term, children have similarities to a child with severe (Kanner's) autism with long-term impairment of behavioural and cognitive functioning.
  • Effects on intellectual function, self-sufficiency and adaptive skills are profound, with most cases regressing to severe intellectual disability.
  • Medical comorbidities such as epilepsy commonly develop.
  • Those with moderate-to-severe mental intellectual disability or with an inability to communicate tend to do worse than those left with a higher IQ and some verbal communication.
  • Outlook is poor. Children will require lifelong support.
  • Risk of seizures increases throughout childhood, peaking at adolescence, and seizure threshold may be lowered by SSRIs and neuroleptics.
  • Life expectancy has previously been reported as normal. However, more recent studies suggest that mortality of people with autistic spectrum disorders is twice that of the general population, mainly due to complications of epilepsy[8] .

In 1908 a Viennese remedial teacher, Theodor Heller, described six children who had insidiously developed a severe mental regression between the third and fourth years of life after previously normal development. He called it dementia infantilis. Dementia infantilis was first distinguished from infantile autism in 1943, when Leo Kanner postulated that they represented separate diagnoses.

Dr Mary Lowth is an author or the original author of this leaflet.

Are you protected against flu?

See if you are eligible for a free NHS flu jab today.

Check now

Further reading and references

  1. Mughal S, Faizy RM, Saadabadi A; Autism Spectrum Disorder. StatPearls, Jan 2020.

  2. Zwaigenbaum L, Szatmari P, Mahoney W, et al; High functioning autism and Childhood Disintegrative Disorder in half brothers. J Autism Dev Disord. 2000 Apr30(2):121-6.

  3. Nunn K, Williams K, Ouvrier R; The Australian Childhood Dementia Study. Eur Child Adolesc Psychiatry. 2002 Apr11(2):63-70.

  4. Fombonne E; Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord. 2003 Aug33(4):365-82.

  5. Kurita H, Koyama T, Setoya Y, et al; Validity of childhood disintegrative disorder apart from autistic disorder with speech loss. Eur Child Adolesc Psychiatry. 2004 Aug13(4):221-6.

  6. Kagan-Kushnir T, Roberts SW, Snead OC 3rd; Screening electroencephalograms in autism spectrum disorders: evidence-based guideline. J Child Neurol. 2005 Mar20(3):197-206.

  7. McDougle CJ, Holmes JP, Bronson MR, et al; Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997 May36(5):685-93.

  8. Mouridsen SE, Bronnum-Hansen H, Rich B, et al; Mortality and causes of death in autism spectrum disorders: an update. Autism. 2008 Jul12(4):403-14. doi: 10.1177/1362361308091653.

newnav-downnewnav-up